Macquarie Group’s Akebia Therapeutics AKBA Stock Holding History

Macquarie Group’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-9,170	Closed	-$17	–	1900
2024 Q1	$17	Buy	+9,170	New	+$14.7K	﹤0.01%	1697
2022 Q2	–	Sell	-3,370	Closed	-$2	–	2567
2022 Q1	$2	Hold	3,370	–	–	﹤0.01%	2610
2021 Q4	$8K	Hold	3,370	–	–	﹤0.01%	2531
2021 Q3	$10K	Hold	3,370	–	–	﹤0.01%	2538
2021 Q2	$13K	Hold	3,370	–	–	﹤0.01%	2440
2021 Q1	$11K	Sell	3,370 -1,033	-23%	-$3.72K	﹤0.01%	2373
2020 Q4	$12K	Hold	4,403	–	–	﹤0.01%	2284
2020 Q3	$11K	Hold	4,403	–	–	﹤0.01%	2265
2020 Q2	$60K	Buy	+4,403	New	+$45.6K	﹤0.01%	1883
2018 Q3	–	Sell	-27,000	Closed	-$269K	–	2146
2018 Q2	$269K	Buy	27,000 +23,100	+592%	+$231K	﹤0.01%	1561
2018 Q1	$37K	Sell	3,900 -15,300	-80%	-$214K	﹤0.01%	2024
2017 Q4	$286K	Buy	19,200 +9,900	+106%	+$164K	﹤0.01%	1629
2017 Q3	$183K	Buy	+9,300	New	+$143K	﹤0.01%	1777

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Macquarie Group's AKBA Position: Q2 2024 in Review

Macquarie Group sold out of Akebia Therapeutics (AKBA) in Q2 2024, closing a stake of 9,170 shares — an estimated $17 sold.

Macquarie Group first reported a position in AKBA in Q3 2017 and held it in 13 quarters. The position peaked at $286K in Q4 2017. 103 funds tracked by Wall St. Rank hold AKBA as of Q2 2024.

Macquarie Group reported no remaining Akebia Therapeutics position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 9,170 Akebia Therapeutics shares in Q2 2024, an estimated $17.
Macquarie Group first reported a position in Akebia Therapeutics in Q3 2017 and held it in 13 quarters.
Macquarie Group's Akebia Therapeutics position peaked at $286K in Q4 2017.
103 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.